PureTech Health PLC Total Voting Rights (5460W)
August 01 2018 - 11:30AM
UK Regulatory
TIDMPRTC
RNS Number : 5460W
PureTech Health PLC
01 August 2018
1 August 2018
PureTech Health plc
Total Voting Rights and Share Capital - Month End Disclosure
Pursuant to DTR 5.6.1 of the Disclosure Guidance and
Transparency Rules:
As at 31 July 2018 the issued share capital of PureTech Health
plc comprised 282,463,969 Ordinary shares of one pence each. There
were no shares held in treasury.
The total number of voting rights in PureTech Health plc is
therefore 282,463,969.
This information may be used by shareholders in their
calculations to determine if they are required to notify their
interest in, or a change to their interest in, PureTech Health plc
under the FCA's Disclosure Guidance and Transparency Rules.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG). The Company has
developed deep insight into the connection between these systems
and the resulting role in many chronic diseases, which represent
the majority of healthcare spend and have proven resistant to
established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech Health has developed new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions. Its Affiliates division includes
two product candidates that are preparing for potential regulatory
approval in the United States and Europe and a number of clinical
and pre-clinical programmes. These affiliates have developed
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading scientific
experts.
PureTech's Internal division (Ariya) is advancing a pipeline
fuelled by recent discoveries in lymphatics and immune cell
trafficking to modulate disease in a tissue-specific manner. These
programmes build on a new understanding of the transport and
biodistribution of various immune system components in order to
develop targeted therapies for diseases with major unmet needs
including cancer and autoimmune and neuroimmune disorders. One of
these programs, which is focused on the oral administration of
nucleic acids and other biologics using milk exosomes, is being
advanced in collaboration with Roche for the potential application
across their antisense oligonucleotides platform.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech Health FTI Consulting
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRUGUGPRUPRGQG
(END) Dow Jones Newswires
August 01, 2018 12:30 ET (16:30 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024